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Background: Currently, far too many older adults consume inappropriate prescriptions, which increase the risk of
adverse drug reactions and unnecessary hospitalizations. A health education program directly informing patients of
prescription risks may promote inappropriate prescription discontinuation in chronic benzodiazepine users.
Methods/Design: This is a cluster randomized controlled trial using a two-arm parallel-design. A total of 250 older
chronic benzodiazepine users recruited from community pharmacies in the greater Montreal area will be studied
with informed consent. A participating pharmacy with recruited participants represents a cluster, the unit of
randomization. For every four pharmacies recruited, a simple 2:2 randomization is used to allocate clusters into
intervention and control arms. Participants will be followed for 1 year. Within the intervention clusters, participants
will receive a novel educational intervention detailing risks and safe alternatives to their current potentially
inappropriate medication, while the control group will be wait-listed for the intervention for 6 months and receive
usual care during that time period. The primary outcome is the rate of change in benzodiazepine use at 6 months.
Secondary outcomes are changes in risk perception, self-efficacy for discontinuing benzodiazepines, and activation of
patients initiating discussions with their physician or pharmacist about safer prescribing practices. An intention-to-treat
analysis will be followed.
The rate of change of benzodiazepine use will be compared between intervention and control groups at the individual
level at the 6-month follow-up. Risk differences between the control and experimental groups will be calculated, and
the robust variance estimator will be used to estimate the associated 95% confidence interval (CI). As a sensitivity
analysis (and/or if any confounders are unbalanced between the groups), we will estimate the risk difference for the
intervention via a marginal model estimated via generalized estimating equations with an exchangeable correlation
structure.
Discussion: Targeting consumers directly as catalysts for engaging physicians and pharmacists in collaborative
discontinuation of benzodiazepine drugs is a novel approach to reduce inappropriate prescriptions. By directly
empowering chronic users with knowledge about risks, we hope to imitate the success of individually targeted
anti-smoking campaigns.
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Appropriate and safe prescribing for older adults is ren-
dered difficult by the increased risk of side effects, drug-
drug interactions and adverse events, due to associated
comorbidities and high prevalence polypharmacy in this
population [1,2]. Prescriptions are considered inappropri-
ate when potential risks outweigh potential benefits, and
safer therapeutic alternatives exist that have similar or su-
perior efficacy [3-5]. Avoiding the use of inappropriate
and high-risk drugs is an important, simple and effective
strategy in reducing medication-related problems and ad-
verse drug events in older adults [5]. The Beers Criteria
for Potentially Inappropriate Medication Use in Older
Adults identifies, grades and qualifies potentially inappro-
priate medications. The criteria were developed by a panel
of geriatric pharmacy experts who applied a modified
Delphi method to a systematic review of all medications
and graded the evidence to reach a consensus on a
recommended list of drugs to avoid in older people [5-7].
Currently, far too many older adults are taking inappro-
priate prescriptions, which further increases the risk of
adverse drug reactions and unnecessary hospitalizations
[5,8-11]. Inappropriate prescribing has been estimated to
occur in 12 to 40% of community-dwelling non-hospitalized
older adults aged over 60 years, depending on the criteria
used and the country studied [3,5,9-14]. A conservative esti-
mate of the incremental healthcare expenditures related to
inappropriate prescribing among community-dwelling older
adults is $7.2 billion in the United States [12].
Benzodiazepines represent one of the most prevalent
inappropriate prescriptions, consumed by 19% of older
adults (range 10 to 42%) [15]. The new Beers list, released
in 2012, recommends that all short- and long-acting benzo-
diazepine sedative-hypnotic drugs used for the treatment of
anxiety and insomnia should be avoided in older adults,
due to an excessive risk of delirium, falls, fractures and
motor vehicle accidents [5,16-19]. Benzodiazepines have
also been shown to increase the risk of amnestic and non-
amnestic cognitive impairment and may lead to incident
dementia [20,21].
Previous research has attempted to define the best
strategy to inform and educate relevant parties, to try
and implement safer prescribing practices, and to eliminate
benzodiazepine use. The problem is that chronic benzo-
diazepine users develop a psychological dependence to
benzodiazepines, and both physicians and consumers
have difficulty implementing tapering protocols [22].
Many patients deny or minimize side effects, or express
reluctance to risk suffering without these medications
[22]. For these reasons physicians are hesitant about
insisting on benzodiazepine discontinuation for fear of
upsetting the doctor-patient relationship or because
they believe that the patient tolerates the medication
with minimal side effects [23].Interventions to reduce benzodiazepine use in older
people have been tested [24-47]. Several approaches have
yielded insignificant results; other approaches, such as
physician-targeted online drug audits, didactic educational
activities and letters from physicians advising on risks
associated with benzodiazepine use, have resulted in
discontinuation rates ranging from 16 to 25% [43-47].
Despite achieving mild success in benzodiazepine discon-
tinuation, these approaches are rarely feasible on a large
scale and can be linked to extensive fees.
Targeting consumers directly as catalysts for engaging
physicians and pharmacists in collaborative discontinuation
of benzodiazepine drugs is a novel approach to reduce
inappropriate prescriptions that has never been tested.
Studies have shown that collaborative efforts to taper
benzodiazepine use do not result in an increased workload
for family physicians [48]. This type of approach could
empower patients to participate in medication safety,
diminish physician workload and do so at lower costs than
current approaches in changing medical practice.
The aim of the current cluster randomized controlled
trial is to determine the effectiveness of an educational




The primary objective of the EMPOWER trial is to
evaluate the effectiveness of a new knowledge transfer tool
on a community-based sample of chronic benzodiazepine
users, as measured by the rate of benzodiazepine discon-
tinuation at 6 months with 1-year follow-up, to determine
whether change rates are sustained over the long-term. The
acronym EMPOWER stands for “Eliminating Medications
through Patient OWnership of End Results”.
Secondary objectives are to determine whether receipt of
a knowledge transfer tool by chronic benzodiazepine users
changes risk perceptions and self-efficacy for discontinuing
benzodiazepines, and leads patients to initiate discussions
about safer prescribing practices with their physician
or pharmacist.Design
This is a cluster randomized controlled trial. The rationale
for choosing a cluster design is to prevent contamination
across the intervention and control arms by individual
clients served by the same pharmacy. The cluster and
unit of randomization is the community pharmacy.
There are two arms in this parallel randomized con-
trolled trial: the educational intervention arm and the
control arm. A 50:50 ratio of participants will be used
in each study arm. Figure 1 illustrates the study flow.
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The study is being conducted in the greater Montreal
area in Quebec, Canada. Collaboration with a drugstore
chain was established, and all pharmacies within a 3-hour
driving radius (approximately 200 km) of Montreal were
identified and listed. Pharmacies were listed in random
order by a computer generated program, contacted sequen-
tially and screened for eligibility criteria. Clusters consist of
community pharmacies with ≥20% older adults. In order to
prevent small or empty clusters, pharmacies with ≤50
eligible participants following the initial screening process
are not recruited to the trial.
Study population
The study population comprises chronic benzodiazepine
users aged 65 years and older.Figure 1 Study flow chart.Eligibility criteria for individual patients to enroll in
the study
Selection of participants will be according to the following
inclusion and exclusion criteria.
Inclusion criteria
1. Men and women aged 65 years and older.
2. With at least five active prescriptions
(polypharmacy).
3. Of which one is an active benzodiazepine
prescription that has been dispensed for at least 3
consecutive months prior to screening, based on
pharmacy records.
4. Patients who are willing to participate in
the study.
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1. A diagnosis of severe mental illness or dementia
ascertained by the presence of an active prescription
for any antipsychotic medication, and/or a
cholinesterase inhibitor or memantine in the
preceding 3 months.
2. Unable to communicate in French and/or English.
3. Evidence of significant cognitive impairment
(score under 21 on the Montreal Cognitive
Assessment (MoCA) [49]).
4. Patients living in a long-term care facility.
Ethical approval
The study protocol was approved on 26 July 2009 by the
Research Ethics Board of the Centre de Recherche de
l’Institut Universitaire de Gériatrie de Montreal, Canada
(ClinicalTrials.gov identifier: NCT01148186).
Enrollment
Enrollment in the trial is conducted in collaboration with a
regional pharmacy chain. A letter from the vice-president
of the chain was sent to all affiliated pharmacies inviting
pharmacists to participate in the trial by recruiting eligible
clients served by their medication dispensing units.
Company headquarters then identified a list of all chain
drugstores within a 3-hour driving radius of the research
center and sent a list to the research team. This list was
sorted in random order by a computer generated program
and pharmacies are contacted systematically to ascertain
their interest in participating in the study. Pharmacies
interested in participating are supplied with a list of eligible
participants identified from the company’s centralized
electronic database by a preset inclusion/exclusion filter
that applies all inclusion and most exclusion criteria.
Any pharmacy found to have less than 50 potential candi-
dates is excluded from the project to avoid small or empty
clusters. Otherwise, pharmacies are enrolled in the study
and proceed with participant recruitment.
Recruitment of participants and application of eligibility
criteria
Recruitment of participants occurs through a three-step
screening process. First, pharmacy clients are filtered by
the company’s centralized computer system using preset
eligibility criteria for age and medication use. Second,
participating pharmacists receive a list of eligible clients
with a matching set of personalized name and address
labels from company headquarters through internal mail,
and are asked to review the list to exclude patients with
undetected dementia or those living in care facilities.
Using the final list of potential participants, pharmacists
tally the numbers and contact the research team to
request an appropriate number of English and Frenchstudy invitational materials intended for mailed distribution
to participants.
Invitational materials consist of a headquarters pre-
approved invitation letter personalized on behalf of the
pharmacist and an accompanying brochure describing a
study on ‘better drug management’. The flyer invites partic-
ipants to contact either their pharmacist directly or the
study coordinator by phone if they have any questions or
are interested in participating in the study. Letters and invi-
tations are put in envelopes by the pharmacy personnel,
affixed with the address labels provided by company head-
quarters and mailed to all eligible participants.
One week after sending out the invitations, the pharma-
cist notes all replies spontaneously received from potential
participants indicating their willingness or refusal to partici-
pate in the study. The pharmacist then calls the remaining
candidates to ascertain their interest in participating in the
study and, if so, to obtain permission to give their names
and phone numbers to the study coordinator. According to
protocol, a maximum of three phone calls and voice
messages must be attempted over a 2-week time period in
order to reach participants, after which time potential
participants are declared not interested. All affirmative
responses are recorded by the pharmacist, and the names
and phone numbers of interested clients are transferred to
the research staff at the end of the 3-week period following
the invitation mail-out to participants.
The study coordinator then contacts all potential
participants referred by the pharmacists (with the client’s
permission) and arranges an appointment at the person’s
residence to complete the third screening stage: signed
consent if eligible and collection of baseline data. During
the home visit, a research assistant reviews the medication
currently taken by the patient, queries the medical history
and administers the MoCA. Signed consent to participate
in the study is then obtained from individuals who meet
the study criteria after baseline cognitive and health status
screening. All baseline data are collected from the ques-
tionnaires indicated in Table 1 under T0 at this time.
Randomization
Randomization
A statistician, blinded to pharmacy and cluster size,
generates a random allocation sequence using computer
generated random digit numbers. For every four pharma-
cies recruited, a simple 2:2 randomization is used to allo-
cate the four clusters into intervention and control groups.
Towards the end of recruitment, randomization might be
skewed to favor the least populated study arm to allow the
desired 50:50 allocation ratio.
Concealment of allocation
Prior to random allocation into either arm of the study,
informed consent, agreement to enroll in the study and
Table 1 Overview of data collection and measurements in both trial arms
Baseline Follow-up post-intervention
Visit number T0 T1 T2 T3 T4
Time 1-7 months pre-intervention 7 days 6 weeks 6 months 1 year





Rey 15-Item Memory Test X
GAI X X X X
Depression PHQ-9 Xa X X X
Insomnia questionnaire Xa X X X
Medication use characteristics X
Benzodiazepine tapering questionnaire X X X X
Medication knowledge questionnaire X X
BMQ-Specific X X
Self-efficacy scale X X
Intervention related questionnaire X X X
Intervention appreciation questionnaire X
aOnly administered if related outcome present. BMQ-Specific, Beliefs about Medicines Questionnaire - Specific segment; GAI, Geriatric Anxiety Inventory; GHS,
general health status; MoCA, Montreal Cognitive Assessment; PHQ, Patient Health Questionnaire; SMAF, functional autonomy measurement system.
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pharmacists and their clients. Up until the point of
randomization, neither the research assistant, the cluster
representative (the pharmacist), nor the client will know
the allocation of the clusters. After randomization, only
the research assistant will be aware of treatment alloca-
tion. Pharmacists and participants will not be informed,
and will remain unaware of the fact that there is another
group in the study; nor will they be informed of the
procedures for the other arm. Participants’ link to the
project will be the pharmacist, but participants of the same
pharmacy will not normally be in contact with each other.
Randomization is performed in clusters to prevent bias in
case this happens. Therefore all participants from the same
pharmacy will be randomized as a single cluster, thereby
receiving the same treatment and remaining blinded to
treatment allocation.
Blinding
As the intervention is educational in nature, blinding of
the intervention is impossible. However, to preserve a
certain level of blinding and to protect sources of bias,
the following measures are taken.
For participants, blinding is achieved by presenting the
project to participants as a project on optimizing medi-
cation management. Consenting participants understand
that their medication profiles will be transmitted to theresearch team within the following months and that they
will receive a customized letter at some point during the
year which may contain recommendations for change,
which they can then decide to take to their physician or
pharmacist for discussion.
For pharmacists, blinding is achieved by presenting the
same study timeline. Pharmacists are aware that their
clients will receive an intervention at some point during the
following year and remain blinded to group allocation
throughout the course of the study. Pharmacists also
remain blinded to other participating pharmacies. Since
pharmacies are randomized as clusters, they are located in
distinct geographic locations and generally have no reason
to interact with one another.
Thus, blinding pertains to both the individual and
cluster level.
The educational intervention
The educational intervention consists of a seven-page
letter-size paper brochure developed specifically for this
trial. The language for the intervention is set at a grade
six reading level and written in 14 point font to facilitate
accessibility of the material. The brochure is mailed to the
intervention group within 1 week of group allocation.
The control/wait-list group receives the educational tool
6 months later. As the intervention is sent individually to
participants and participants within each cluster are
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the individual participant.
Theory and development of the intervention
The tool aims to promote active learning by using
constructivist learning theory principles, incorporated
during the development of the intervention. Constructivist
learning theory activates users to create new knowledge in
order to make sense out of the presented material. The
goal of this approach is to allow the learner to interact
with the academic material, fostering their own selecting,
organizing and information integrating processes [50].
Many other learning theories were integrated in the
different parts of the intervention, such as cognitive
dissonance, social comparison, peer champion theories
and self-assessment theory. Cognitive dissonance theory
confronts two inconsistent cognitions held simultaneously
by the same individual. This process aims to create an
aversive motivational state in the individual who will then
seek to alter one of these perceptions to remove the pres-
sure caused by this conflict [51]. The tool also includes
elements of social comparison and peer champion theor-
ies [52]. Social comparison consists of comparing oneself
to others in order to evaluate or enhance personal aspects
[53]. Thus, the evaluation of the ability or inability to
accomplish a certain action depends on a proxy performer’s
success. The efficacy of social comparison depends on
whether the comparer assimilates or contrasts him/herself
to others [52]. Thus, aspects such as previous agreement
with the peer’s views and comparability with the peer
champion are paramount for the comparison to work [53].
A self-assessment component was also introduced to
promote insight about potential misinformation or beliefs
held about benzodiazepine use [54,55]. A common idea in
models of risk perception is that risk is perceived from two
dimensions: knowledge of and beliefs. Information about
the risks associated with benzodiazepine use was therefore
in incorporated into the tool. It has also been shown that
pre-existing beliefs frequently supersede information trans-
fer about risks [56]. In order to understand the drivers and
consequences of risk perception the behavior motivation
hypothesis was used. This hypothesis, which is endorsed by
most models of health behavior, describes the determinants
of risk perception and their effects on behavior change [57].
It is important to note that perception of risk has been
shown to be positively related to preventive health behavior
in conditions where expectations of success in dealing with
the risk are acceptable and when recommendations for
preventive behavior are presented as effective [58].
The textual content of the intervention was based on
guidelines concerning the use of benzodiazepines in
older people as well as a systematic review of the evidence.
The initial content of the tool was drafted by a geriatrician
and graduate student, and then validated by a panel ofcolleagues with expertise in geriatric pharmacy. Following
validation, a health librarian reviewed the content to ensure
that the wording met standards for patient literacy. The
tool was initially developed in English then backward-
forward translated into French.
Components of the intervention
The cover page of the brochure has an image of a
pillbox filled with several medications titled ‘You May
Be At Risk’, followed by ‘You are currently taking
(name of benzodiazepine)’. Brochures are customized
according to each patient’s medication profile. The first
page of the intervention lists four true or false questions
regarding the safety, side effects, withdrawal symptoms
and alternatives to the use of the benzodiazepines, and is
entitled ‘Test Your Knowledge’. The second page contains
the correct answers as well as an explanation for each
statement. The goal is to create cognitive dissonance and
challenge the patient’s beliefs for each incorrect answer by
incorporating elements of constructivist learning theory
into the answers. The third page incorporates a self-
assessment component as well as educational facts on
potential inappropriate use, side effects, drug-drug
interactions and information about physiological changes
that occur with age that affect drug metabolism. Sugges-
tions for equally or more effective therapeutic substitutes,
as well as evidence-based risks associated with benzodi-
azepine use in older people, are presented on the fourth
and fifth pages. The sixth page highlights one woman’s
success story in weaning herself off benzodiazepines. The
last page outlines a simple 21-week tapering program that
can be adapted to the patient’s medication use. For contrast
and visual enhancement, visual such as color shading and
several pictures of older adults and medication are used
throughout the tool. In order to make sure the intervention
is used appropriately, the words ‘Please Consult your
Doctor or Pharmacist Before Stopping Any Medication’
appear as a warning in large lettering on four different
occasions throughout the tool.
Acceptability of the intervention
To determine the readability and comprehension of the
information, the tool was field-tested in six focus groups of
older adults (n = 60). Based on the focus group feedback,
elements of the tool, such as the wording, ordering of the
material and the visual presentation were changed in an
iterative process until acceptability was reached.
Study arms
Participants allocated to the experimental group receive
the written educational program via mail immediately
following randomization. Telephone follows-ups are
conducted 1 week, 1 month, 6 months and 1 year post-
intervention, and last 5 to 10 minutes. Participants in
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first 6 months following randomization and then receive
the same intervention as the experimental group.Study outcomes
Outcomes are measured at all study follow-up points. At
baseline, questionnaires are completed at the participants’
homes during an interview with the research coordinator.
Follow-up is by telephone interview with the same
coordinator. Self-reported socio-demographic variables,
health status variables and prescription details are collected
at baseline.Primary outcomes
Prescription change rate at 6 months
The primary outcome of the study is cessation of ben-
zodiazepines in the 6 months following receipt of the
intervention, ascertained by pharmacy renewal profiles
and confirmed by patient self-report. A 1-year follow-
up will be undertaken to determine whether change
rates are sustained over the long-term. The definition of
discontinuation will be an absence of any benzodiazepine
prescription renewal at the time of the 6-month follow-up.
Dose reductions will also be measured and will be defined
as ≥50% reductions in the renewal profile for at least 3
consecutive months beginning at the time of the 6-month
follow-up. The discontinuation/dose reduction rate among
participants in the experimental arm will be compared
to the discontinuation/dose reduction rate among
participants in the control arm. In this way we will be
able to determine the absolute rate of discontinuation
attributable to the intervention. This outcome measure
pertains to the individual level.
The 6-month period and 1-year follow-up were chosen
because although there is no agreement on the time
frame of change, the trans-theoretical model supposes
that, typically, once people start thinking about changing
their behavior, decision and planning of the action is
usually done within the following 6 months. Maintenance
of the new behavior begins after 6 months of being in the
active stage of changing and continues for at least 6 months
[59]. Pharmacy profiles, supplied monthly by fax to the
research center by the pharmacist, were chosen to measure
prescription change rates because of the high amount of
information they contain. Pharmaceutical profiles vary in
the information they contain between pharmacies of the
same chain depending on the owners. However, vital
information to determine change rates, such as the date of
renewal, the dose and the quantity of the prescription
are always listed. Using this objective measure allows
comparison and validation of patient reported outcomes,
and thus more accurately and objectively determines the
effect of the intervention.Secondary outcomes
Change in risk perception
Change in perception of risk associated with benzodi-
azepine use will be evaluated through a self-reported
measure, along with change in knowledge and change
in beliefs. The self-reported measure will consist of
participants answering whether they perceived the same,
increased or no risk from consumption of their benzodi-
azepine medication after having read the brochure, and
will be collected 1 week post-intervention. Change in
knowledge will be measured by comparing the pre- and
post-intervention (T1) answers from the four true or false
questions in the ‘Test Your Knowledge’ section of the
questionnaire. The first statement targets safety of long-
term benzodiazepine and reads, ‘(Example: ValiumW) . . . is
a mild tranquilizer that is safe when taken for long periods
of time’. The second statement focuses on side effects and
is phrased, ‘The dose of ValiumW that I am taking causes no
side effects’. The third statement, focusing on withdrawal, is
worded, ‘Without ValiumW I will be unable to sleep or will
experience unwanted anxiety’, and the fourth, on alternative
treatment options, states, ‘ValiumW is the best available op-
tion to treat my symptoms’. Change in beliefs is measured
by comparing the pre- and post-intervention (T1) total
scores on the Specific section of the beliefs about medicines
questionnaire (BMQ-Specific) adapted for benzodiazepines
[60,61]. Statements remained identical to the originals with
the exception that the word ‘medicines’ was replaced
by ‘benzodiazepine’ in each statement. The beliefs in
medications questionnaire is a validated measure used
to assess cognitive representations of medications [60,61].
These outcome measures pertain to the individual level.
Change in risk perception was chosen as a secondary
outcome in order to reflect the behavior motivation
hypothesis described earlier. As patient reported outcomes
are not always objective, two additional and more objective
outcomes were chosen to evaluate risk perception: change
in knowledge and change in beliefs about benzodiazepines.
This was done because a common idea in models of
risk perception states that risk is perceived from two
dimensions: knowledge of and beliefs about that risk,
as mentioned earlier. The rationale for choosing the
score for the knowledge questionnaire was that it allows a
quantification of the knowledge transfer aspects of the
intervention. The rationale for choosing the BMQ-Specific
instrument to measure beliefs relates to its ability to isolate
and score participants’ beliefs about a specific medication;
both in terms of the dangers and concerns participants
have regarding their prescription (Specific-Concerns), and
the necessity they attribute to this same prescription
(Specific-Necessity). The BMQ-Specific consists of two
5-item factors belonging to each sub-score. Participants
indicate their degree of agreement with each statement on
a 5-point Likert scale (1 = strongly disagree to 5 = strongly
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scores (5 to 25 scale) with higher scores indicating stronger
beliefs in that concept. A necessity-concerns differential
can also be derived from these scales by subtracting the
concern sub-score from the necessity sub-score. This
differential can be considered as the cost benefit analysis
for each patient, where costs (concerns) are weighed against
perceived benefits (necessity beliefs) [60,61].Change in self-efficacy
The second secondary outcome measure will be change
in self-efficacy. Self-efficacy will be measured pre- and
post-intervention (T1) with the medication reduction
self-efficacy scale, a scale that was developed and tested
in the context of previous benzodiazepine tapering
studies [62]. Participants will indicate their level of
confidence for achieving a pre-determined medication
reduction goal on a scale of 0 to 100 (0 = not at all
confident to 100 = extremely confident), which is based
on Bandura’s original guidelines for the development of
task-specific self-efficacy scales. Post-intervention, partici-
pants will also be asked to rate on this same scale their
level of confidence about eventually discontinuing using
the tapering program provided. This outcome measure
pertains to the individual level. The rationale is that self-
efficacy gives a clear indication of a patient’s belief about
their capability to discontinue benzodiazepines and may be
a potential predictor of benzodiazepine discontinuation.Initiation of discussion with a physician or pharmacist
about the decision to taper benzodiazepines
The third secondary outcome will be the potential of the
intervention to activate participants to discuss safer
prescribing options with their physician or pharmacist.
At T1 to T3 participants will be asked to indicate: if they
had spoken to friends and/or family about the interven-
tion, and if they had spoken to or intended to discuss
medication discontinuation with either their physician or
pharmacist. Reactions and results of these behaviors will
be noted. These intentions are considered as measures of
self-initiated medication risk reduction behaviors. This
outcome measure pertains to the individual level.
The intervention was designed to target consumers dir-
ectly as catalysts for engaging physicians and pharmacists
in collaborative discontinuation of their benzodiazepine
drugs or other inappropriate medications. Observing this
outcome will allow us to determine the intervention’s
potential for engaging participants in collaborative medica-
tion management. Furthermore, it will also allow us to
identify at which point the intervention failed, and whether
psychological dependence on the part of consumers or
obstructive behavior on the part of the physicians or phar-
macists was the cause of the intervention’s failure.Sample size
The main question driving the sample size for this study
is whether chronic inappropriate medication users who
receive the knowledge transfer tool are more likely to
discontinue use at 6-month follow-up compared to users
who do not receive the intervention. A systematic review
was undertaken to identify similar studies and compare
discontinuation rates for benzodiazepine drugs. Inclusion
criteria were: rigorous randomized controlled trial
methodology, inclusion of adults aged 65 years and older,
community setting, a non-imposed intervention, and
interventions that targeted inappropriate benzodiazepine
prescriptions and included a prescription discontinuation
measure. Eight studies met the inclusion criteria and were
used in the sample size calculation estimates. Many other
studies were identified that presented very different esti-
mates, however these varied greatly in setting, population
or measure and were irrelevant to the current study.
We expect our intervention to achieve a rate of
discontinuation that is at least as great as that achieved in
previous studies by medication review by pharmacist and
contact with physician (range 19 to 24%, mean 22%)
[29,43,63] or by simple discontinuation letters (range 13
to 20%, mean 16%) [47,64-67]. However, it is possible that
individuals who do not receive the intervention may have
rates of discontinuation as high as 6% for inappropriate
prescriptions (range 2 to 6%, mean 4%) [29,43,47,64-66].
Our study will therefore be powered to detect a minimal
20% increase in inappropriate medication discontinuation
due to use of the intervention and an absolute minimal
rate of discontinuation of 25%. Based on an alpha of 0.05
and 80% power to detect a 20% difference, 58 participants
are needed for each group. To detect greater differences, a
lower sample size is needed. However, due to the cluster
design of this study, adjustments need to be made to
account for both clustering and for the effect of the coeffi-
cient of variation of the cluster size [68]. Based on current
recruitment data (16 clusters, cluster sizes 6 to 27), the
coefficient of variation was established at 0.527 using the
minimum/maximum cluster size estimation method [68]
and estimated intra-cluster correlation set at 0.05.
After computing the coefficient by which to multiply
our sample size to account for these factors we
obtained 1.79 [69]. Current loss to follow-up in the study
(in the first 185 recruited participants) was established at
9%. Therefore 114.2 (58 × 1.79 × 1.10 = 114.2) participants
will be needed for each group. A sample of 250 individuals
will be recruited.
Analysis plan
Data will be analyzed using an intention-to-treat approach.
Descriptive statistics (means, proportions) will first be
calculated to assess the balance between the groups on
important confounders, such as age, sex, health status,
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use. In order to answer the main research question driving
this study - whether an educational intervention targeting
consumers directly as catalysts for engaging physicians
and pharmacists in collaborative discontinuation achieves
an inappropriate prescription discontinuation rate of at
least 20% compared to usual care - we will use a marginal
model estimated via generalized estimating equations
(GEE) with a binary outcome and an identity link, with
an exchangeable correlation structure to account for
correlation between participants in the same cluster [69].
Risk differences between the control and experimental
groups will be calculated and the robust variance estimator
will be used to estimate the associated 95% confidence
interval (CI) and P value [70]. As a sensitivity analysis
(and/or if any confounders are unbalanced between the
groups), we will estimate the risk difference for the
intervention via a marginal model estimated via GEE
with an exchangeable correlation structure. The robust
variance estimator will again be used. In secondary
analyses, we will calculate risk differences in subgroups
of interest (for example, very older people, women, baseline
beliefs about medication and degree of polypharmacy).
The analysis will be carried out at both the cluster and
individual levels.
In order to determine whether the patient intervention
altered beliefs about the necessity-concern ratio, knowledge
or risk perception for the inappropriate prescriptions, as
well as self-efficacy, paired t-tests will be used to evaluate
change scores pre- and post-intervention. The potential of
the intervention to engage participants in preventive health
behaviors will be evaluated via chi-square tests comparing
intervention and control groups. These analyses will be
carried out at the individual level.
Discussion
To date there is no effective or sustainable approach to
reduce benzodiazepine use in older adults [24-42]. Pre-
vious research on strategies to reduce benzodiazepine
consumption has applied paternalistic approaches to
patient care, similar to the ‘top-down’ managerial approach
described in management and organizational development
theory [71,72]. An example of this approach is when
physicians acquire warning letters from study investigators
and send these letters to patients asking them to schedule
an office visit to discuss benzodiazepine discontinuation.
Our educational intervention draws on theories of self-
management and collaborative doctor-patient partnerships,
and provides a means to test a ‘bottom-up’ change strategy
[71,72]. In the bottom-up model, patients drive prescrip-
tion decisions from information gathered on the Internet,
through friends or via an accredited academic body. To
our knowledge, no published study to date has targeted
the patient as a driver of safer prescribing practices. Bydirectly empowering chronic users with knowledge
about risks, suggestions for lower-risk therapeutic options
and self-efficacy for implementing tapering protocols,
we hope to imitate the success of individually targeted
anti-smoking campaigns [73].
To maintain the generalizability of the findings from
our study, exclusion criteria have been kept to a mini-
mum. In order to fulfill recruitment needs, no limits on
cluster size were imposed to pharmacies meeting the
cluster eligibility criteria. Since some pharmacies identi-
fied over 200 potential participants, while others barely
covered the 50 potential candidate minimum to qualify
as a cluster, cluster sizes are expected to vary. However,
this was considered both in the sample size calculations
and analyses.
The study has been designed as a pragmatic trial that
takes place in the real-world setting. The intervention is
theoretically-based and incorporates a practical and
contemporary learning and psychological approach to
help participants overcome hard-to-achieve lifestyle
modifications. Thus, we expect that implementing an
educational intervention trial in a practical setting will
yield both internally and externally valid evidence for
reducing inappropriate benzodiazepine use, by directly
targeting and activating community-dwelling older adults
in a previously unexplored approach.
Trial status
The trial is currently recruiting participants and was
approximately 80% complete at time of publication.
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